News

20210506-labiotech-article-picture

May 6, 2021

Labiotech discussing our proactive approach

Victor Kotsev has evaluated a broad range of initiatives following the COVID-19 pandemic. He also highlights Leyden Labs' proactive approach toward viral diseases amongst a range of vaccine and treatment options. 

20210506-foto-biospace-artikel-mei-2021

April 28, 2021

Leyden Labs featured in BioSpace looking beyond COVID-19 pandemic

Heather McKenzie recently wrote an article about pandemic preparedness. She explores future threats and a collection of measures to protect against future outbreaks. You can read the full article on the BioSpace website. 

20210420-image-GV-interview-youtube

April 13, 2021

Koenraad Wiedhaup and David Schenkein talk about Leyden Labs' approach to pandemic preparedness

Learn more about our story in the conversation between Koenraad Wiedhaup (CEO) and David Schenkein (General Partner at GV and board member at Leyden Labs). They discuss the mission and approach, investment round, fantastic team and plans for the future. 

John-Martin-news

March 31, 2021

John Martin - In Memoriam

The passing of John Martin, who served as a member of our Supervisory Board came unexpectedly and has left us with great sadness. Our thoughts are with his family and his friends. 

bioworld-article-image

March 29, 2021

BioWorld published an article about our Series A

Cormac Sheridan wrote an article about our investment round with GV (formerly Google Ventures), F-Prime, Casdin Capital and Brook Byers. To learn more about our Series A and our story, visit the BioWorld website. 

Endpoints News Logo

March 26, 2021

Leyden Labs' story covered in Endpoints News

Leading up to the public launch, our CEO Koenraad Wiedhaup spoke with Amber Tong of Endpoints News about Leyden Labs. An interesting read to learn more about our mission to free humanity from the burden of respiratory viruses.  

news-item

March 25, 2021

Leyden Labs to Unlock a New Generation of Preventative Medicines against Known and Future Viruses by Securing a €40 Million Series A from GV (formerly Google Ventures), F-Prime and Casdin Capital

Funding to advance platform and portfolio of intranasal products that protect against a broad range of respiratory viruses, including influenza and coronaviruses, to let people live their lives freely

LL-Blue

Adress

Keizersgracht 290 A
1016 EW Amsterdam
The Netherlands

Locations

Amsterdam
Boston


Stay updated

© Leyden Labs, 2021  |  Privacy Policy  |  Design by Ape to Zebra

Back to top Arrow